Chiusura precedente | 0,0000 |
Rendimento dall'inizio dell'anno (YTD) | N/D |
Coefficiente di spesa (netto) | N/D |
Categoria | N/D |
Ultimo guadagno in conto di capitale | N/D |
Valutazione Morningstar | N/D |
Valutazione di Morningstar (rischio) | N/D |
Rating di sostenibilità |
Attivi netti | N/D |
Beta (mensile su 5 anni) | N/D |
Rendimento | N/D |
Rendimento medio 5a | N/D |
Turnover portafoglio titoli | N/D |
Ultimo dividendo | N/D |
Media per la categoria | N/D |
Data di inizio disponibilità | N/D |
Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali® (ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broa
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and commence trading today on the SIX Swiss ExchangeSpin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicinesNovartis pipeline one of the industry’s most competitive, focused on key next-generation platforms and four core therapeutic areasCo
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide5–9 Novar